Kenvue
KVUE
$19.88
+4.41%
Kenvue Inc. is the world's largest pure-play consumer health company, operating across three segments — Self Care (Tylenol, Listerine, Nicorette), Skin Health and Beauty (Neutrogena, Aveeno, Johnson's), and Essential Health — with a portfolio of iconic brands spun out of Johnson & Johnson's consumer segment in May 2023. As a newly independent, scale-driven consumer staples platform generating over $15 billion in annual revenue, Kenvue's identity is defined less by organic innovation than by brand stewardship, pricing power, and cash generation in mature, low-growth categories. The dominant investor narrative is no longer standalone execution but the pending all-cash acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has effectively converted KVUE into a merger-arbitrage instrument where price action tracks deal probability rather than fundamentals. Residual debate centers on integration risk, potential antitrust or regulatory friction, litigation overhangs (notably product liability), and whether the deal spread adequately compensates holders for the time value and closing uncertainty.…
KVUE
Kenvue
$19.88
Related headlines
KVUE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.50 and implied upside of -1.9% versus the current price.
Average Target
$19.50
0 analysts
Implied Upside
-1.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Twelve analysts cover Kenvue with a consensus recommendation of "hold" and a mean rating of 2.786 (on a 1-5 scale where higher is more bearish), indicating a neutral-to-cautious stance. The average target price of $19.50 implies roughly +3.1% upside from the current $18.91, a thin spread that is typical of a stock trading near its merger consideration rather than one priced on standalone fundamentals. Consensus estimates call for EPS of $1.427 and revenue of $17.43 billion, and the muted upside to target suggests the Street views the shares as fairly valued pending deal closure.\n\nThe target range spans $18.00 to $23.00 — a $5.00 spread, or roughly 26% of the current price — signaling meaningful uncertainty about deal terms and completion. The high target of $23.00 would require either an improved exchange ratio, multiple expansion on standalone earnings, or a competing bid, while the low target of $18.00 (about 4.8% below the current price) prices in deal breakage, integration friction, or litigation-driven margin compression. Institutional ratings show a consistent pattern of Neutral/Equal Weight/Hold reiterations from UBS, Barclays, Citigroup, and Canaccord Genuity through 2026 with no upgrades, reinforcing that coverage is maintenance-level and conviction is low — consistent with a merger-arbitrage situation where fundamental research has limited marginal value.
Bulls vs Bears: KVUE Investment Factors
The bull case rests on a pending Kimberly-Clark acquisition that anchors price near the $19.50 consensus target, 34.02% trailing-year outperformance versus SPY, expanding gross margins (56.53% to 58.18%), and $2.117 billion of TTM free cash flow supporting a 4.80% yield. The bear case centers on a thin +3.1% deal spread, a payout ratio of 1.076 that exceeds earnings, a sub-1.0 current ratio, and only 3.02% revenue growth that leaves little standalone value. On balance, the evidence favors neither side strongly — this is a merger-arbitrage instrument where deal probability, not fundamentals, drives returns, and the 'hold' consensus with a 2.786 mean rating reflects that neutrality. The single most important tension is whether the Kimberly-Clark transaction closes on schedule in H2 2026 at terms near the current price; a confirmed closing caps upside near $19.50-$20.13, while any antitrust, litigation, or integration setback that raises breakage risk would expose the stock to its standalone valuation and the $14.02 floor.
Bullish
- Merger arbitrage floor supports price: The pending all-cash Kimberly-Clark acquisition, announced November 2025 and expected to close in H2 2026, anchors the share price near the $19.50 average analyst target, just +3.1% above the current $18.91. With 12 analysts at a 'hold' consensus and a narrow $18.00-$23.00 range, the market is pricing deal completion rather than standalone fundamentals, which limits downside if the transaction proceeds.
- Relative strength outperformance over 12 months: KVUE is up 34.02% over the trailing year versus SPY's 15.53%, an 18.49 percentage point relative strength advantage. The stock sits at roughly 80% of its 52-week range ($14.02-$20.13), confirming a sustained recovery trend rather than a broken chart.
- Improving margins and earnings trajectory: Gross margin expanded from 56.53% in Q4 2025 to 58.90% in Q1 2026 and 58.18% in Q2 2026, while net income rose from $330 million (8.73% margin) in Q4 2025 to $474 million (12.13%) in Q1 2026 and $456 million (11.53%) in Q2 2026. Operating income of $699 million in Q2 2026 compares favorably to $629 million in Q3 2025.
- Robust free cash flow covers dividend: TTM free cash flow of $2.117 billion comfortably funds quarterly dividends of $398 million, with Q2 2026 alone generating $826.8 million of FCF on $688 million operating cash flow against $138.8 million capex. The 4.80% dividend yield is well above the typical consumer staples yield, providing income support while the deal closes.
Bearish
- Thin deal spread limits upside: The average analyst target of $19.50 implies only +3.1% upside from $18.91, and the low target of $18.00 sits 4.8% below the current price. This narrow spread means holders are compensated poorly for the time value and closing uncertainty between now and H2 2026.
- Dividend exceeds earnings: The payout ratio of 1.076 means the 4.80% dividend slightly exceeds net income, relying on free cash flow rather than earnings for support. This is a capital-return policy choice ahead of the Kimberly-Clark combination rather than an earnings-funded commitment, creating risk if FCF deteriorates.
- Liquidity tightness and leverage: A current ratio of 0.958 is below 1.0, indicating modest short-term liquidity tightness, while debt-to-equity of 0.79 and $90 million of quarterly interest expense add balance-sheet burden. ROA of 6.99% and ROE of 13.66% are serviceable but not fortress-like for a staples platform.
- Low-growth top line caps standalone value: Revenue grew just 3.02% year-over-year in Q2 2026 to $3.955 billion, characteristic of low-single-digit consumer staples. With Self Care at $1.589 billion, Essential Health at $1.253 billion, and Skin Health at $1.113 billion, the investment case rests on margin and cash flow rather than any acceleration.
KVUE Technical Analysis
Kenvue is in a sustained recovery uptrend, with the stock up 34.02% over the trailing year versus a 15.53% gain for SPY — a relative strength advantage of 18.49 percentage points. At $18.91, the shares sit at roughly 80% of the 52-week range (low $14.02, high $20.13), positioning them in the upper portion of the band but still about 6.1% below the high, consistent with a stock grinding toward a deal-related ceiling rather than an overextended momentum name. The 25.7% max drawdown over the period underscores that this recovery followed a meaningful prior decline, so the trend is best characterized as repair, not breakout.\n\nShort-term momentum is re-accelerating: the stock is up 6.06% over the past month versus just 1.22% for SPY, a 4.84-point relative strength spread, and the most recent session added 1.29% on a close of $18.91 versus $18.67 prior. That one-month surge contrasts sharply with the 3-month change of -0.37% (versus SPY +2.69%, a -3.06 point relative deficit), revealing a V-shaped pattern — a September drawdown from the ~$19.20 August highs to the $17.60s, followed by an October rebound. The 6-month change of +7.38% is essentially in line with SPY's +7.48%, confirming that the recent burst is mean reversion off the September dip rather than a new secular leg higher.\n\nKey technical levels are well defined: resistance at the 52-week high of $20.13, with the July/August consolidation zone around $19.20-$19.80 acting as intermediate supply, and support at the September lows near $17.60, with the 52-week floor at $14.02 as the deeper backstop. A decisive break above $20.13 would signal the market assigning a higher probability to deal completion or an improved exchange terms outcome; a breakdown below $17.60 would suggest rising skepticism on the merger. Beta of 0.447 — roughly 55% less volatile than the market — is consistent with a consumer staples merger-arbitrage profile and implies modest position-sizing risk, though it also means the stock will likely underperform in a broad rally and its idiosyncratic deal risk dominates factor exposure.
Beta
0.45
0.45x market volatility
Max Drawdown
-23.1%
Largest decline past year
52-Week Range
$14-$20
Price range past year
Annual Return
+30.9%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | +11.3% | -1.2% |
| 3m | +3.1% | +3.4% |
| 6m | +13.7% | +7.0% |
| 1y | +30.9% | +14.4% |
| ytd | +14.8% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Revenue is growing modestly but steadily: Q2 2026 revenue of $3.955 billion rose 3.02% year-over-year from $3.839 billion in Q2 2025, and the trailing four quarters total approximately $15.42 billion ($3.764B + $3.780B + $3.909B + $3.955B). The sequential trajectory — $3.764B in Q3 2025, $3.780B in Q4 2025, $3.909B in Q1 2026, $3.955B in Q2 2026 — shows consistent quarter-over-quarter expansion, with the latest quarter the strongest of the sequence. Segment mix shows Self Care as the largest contributor at $1.589 billion, ahead of Essential Health at $1.253 billion and Skin Health and Beauty at $1.113 billion; the growth profile is characteristic of low-single-digit consumer staples, implying the investment case rests on margin and cash flow rather than top-line acceleration.\n\nProfitability is solid and improving: Q2 2026 net income was $456 million on a 58.18% gross margin ($2.301 billion gross profit), with net margin of 11.53% and operating margin of 17.67%. The multi-quarter trend is constructive — net income rose from $330 million in Q4 2025 (8.73% margin) to $474 million in Q1 2026 (12.13%) to $456 million in Q2 2026, while gross margin expanded from 56.53% in Q4 2025 to 58.90% in Q1 2026 and 58.18% in Q2 2026. Operating income of $699 million in Q2 2026 compares favorably to $629 million in Q3 2025 and $692 million in Q2 2025, and the 58%+ gross margin is typical-to-strong for branded household and personal products, reflecting pricing power in Tylenol, Listerine, and Aveeno.\n\nThe balance sheet is serviceable but not fortress-like: debt-to-equity of 0.79, a current ratio of 0.958 (below 1.0, indicating modest liquidity tightness), and ROE of 13.66% with ROA of 6.99%. Free cash flow is robust at $2.117 billion TTM, and Q2 2026 alone generated $826.8 million of FCF on $688 million of operating cash flow against $138.8 million of capex, while dividends of $398 million per quarter are comfortably covered by cash generation. The 4.80% dividend yield with a payout ratio of 1.076 signals the dividend slightly exceeds earnings and is supported by FCF rather than net income — sustainable near-term but a reminder that the payout is a capital-return policy choice ahead of the Kimberly-Clark combination rather than an earnings-funded commitment.
Quarterly Revenue
$4.0B
2026-06
Revenue YoY Growth
+3.0%
YoY Comparison
Gross Margin
58.2%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Because Kenvue is profitable (Q2 2026 net income of $456 million; TTM EPS of $0.0446 is distorted by one-off items, but the quarterly run-rate of $0.24 implies roughly $0.95 annualized), the PE ratio is the appropriate primary metric. The trailing PE of 22.32x compares with a forward PE of 15.26x — a 31.6% compression that implies the market expects meaningful EPS growth, consistent with consensus estimated EPS of $1.427 versus the current run-rate. The PEG ratio of 0.524 suggests the stock is inexpensive relative to its growth rate, though for a merger target the more relevant anchor is the deal price rather than standalone multiples.\n\nRelative to the consumer staples sector, Kenvue screens cheap on most measures: PS of 2.18x, EV/Sales of 2.81x, EV/EBITDA of 13.77x, and P/B of 3.06x, with a 4.80% dividend yield that is well above the typical staples yield. The forward PE of 15.26x is a discount to the broader market and to premium staples peers, which is justified by Kenvue's low-single-digit revenue growth (3.02% YoY), sub-1.0 current ratio, and the structural overhang of an unresolved merger — the discount is compensation for deal risk, not a mispricing.\n\nHistorically, Kenvue's own valuation band has compressed dramatically: the PE ratio was 35.58x in Q4 2024 and 35.26x in Q1 2025, versus 22.32x today, while PS fell from 11.17x in Q4 2024 to 2.18x currently (the PS series is distorted by share-count and data inconsistencies, but the direction is clear). The stock now trades near the low end of its post-IPO valuation range, which reflects both fundamental maturation (margin expansion lifting the earnings denominator) and the market pricing the pending Kimberly-Clark acquisition — a deal-arbitrage discount rather than a standalone value opportunity.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but real. The dividend payout ratio of 1.076 means the 4.80% yield exceeds net income, so the $398 million quarterly payout depends on the $2.117 billion TTM free cash flow rather than earnings, and any FCF compression would force a policy rethink. A current ratio of 0.958 sits below 1.0, signaling modest liquidity tightness, while debt-to-equity of 0.79 and $90 million of quarterly interest expense add fixed obligations. Revenue concentration is also a factor: Self Care at $1.589 billion is the largest segment, and with total revenue growing only 3.02% year-over-year, the company depends on pricing power in Tylenol, Listerine, and Aveeno rather than volume expansion to sustain margins.
Market and competitive risks are dominated by the merger. The stock trades at a forward PE of 15.26x versus a trailing 22.32x, a discount that is compensation for deal risk rather than a mispricing, so any deterioration in deal probability would compress the multiple toward standalone levels. Beta of 0.447 means the stock is roughly 55% less volatile than the market, but that low beta also means idiosyncratic deal risk dominates factor exposure — KVUE will likely underperform in a broad rally. Recent coverage from Zacks (September 2026) warns investors to brace for integration risks and near-term volatility as the deal nears closing, and Benzinga (February 2026) flagged product litigation and analyst downgrades as persistent headwinds. Competitive disruption in consumer health from private-label brands and the structural maturity of the categories limit any standalone re-rating.
In a worst-case scenario, the Kimberly-Clark deal breaks on antitrust or integration concerns, litigation overhangs escalate, and the stock re-prices to standalone fundamentals. The 52-week low of $14.02 represents a 25.9% decline from the current $18.91, and the 25.7% max drawdown over the trailing period shows this magnitude is historically realistic for this name. The analyst low target of $18.00 (-4.8%) captures only mild skepticism, so a true breakage scenario would likely overshoot that floor toward the $14-$16 zone, implying losses of roughly 15-26% from current levels.